Schiff Advises Altaris on its Agreement to Acquire $1.55 Billion Perrigo’s Prescription Pharmaceuticals Business

News

Schiff Advises Altaris on its Agreement to Acquire $1.55 Billion Perrigo’s Prescription Pharmaceuticals Business

News Release |

Schiff Hardin LLP represented Altaris Capital Partners, LLC, a private investment firm focused on the healthcare industry, in its agreement to acquire Perrigo Company plc’s prescription pharmaceuticals business (Rx) for $1.55 billion. The acquisition is expected to close in 2021.  Perrigo’s Rx business is a leader in the generic prescription pharmaceutical industry.